188 related articles for article (PubMed ID: 35413417)
1. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor.
Desai J; Patel B; Gite A; Panchal N; Gite S; Argade A; Kumar J; Sachchidanand S; Bandyopadhyay D; Ghoshdastidar K; Patel H; Chatterjee A; Mahapatra J; Sharma M; Giri P; Kumar S; Jain M; Sharma R; Desai R
Bioorg Med Chem Lett; 2022 Jun; 66():128728. PubMed ID: 35413417
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
Xiang J; Wang Y; Wang W; Yu J; Zheng L; Hong Y; Shi L; Zhang C; Chen N; Xu J; Gong X; Zhang Z; Cui H; Zhou Q; Zhang D; Liu Y; Ke Y; Shen J; Xia G; Bai X
Bioorg Chem; 2023 Nov; 140():106765. PubMed ID: 37582330
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Zhu X; Luo H; Cong X; Wang J; Liu F
Bioorg Med Chem; 2019 Jun; 27(12):2592-2597. PubMed ID: 30926315
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
6. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
8. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
[TBL] [Abstract][Full Text] [Related]
9. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
Hernandez-Rocha C; Vande Casteele N
Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
[TBL] [Abstract][Full Text] [Related]
11. Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis.
Zhang X; Xu X; Chen J; Wang G; Li Q; Li M; Lu J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111086. PubMed ID: 37883818
[TBL] [Abstract][Full Text] [Related]
12. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
[TBL] [Abstract][Full Text] [Related]
13. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
16. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
18. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
